Seoul Economic Daily EnglishCodex · 实盘不做把握 6/10
北京时间·🕒 发布 15:03:25时区推断·⟳ 抓取 15:56:19·⚡ 决策 07-24 15:57:31 +1m12s·95.2 天前
Celltrion向EMA提交Zymfentra类风湿关节炎适应症III期临床计划
本次只是向EMA提交III期临床计划，距离52周治疗期完成、申报获批和商业化仍远，短线不构成可执行重定价催化。
📄 原文Seoul Economic Daily English↗ 原文
Celltrion Files Phase 3 Trials for Zymfentra in US, Europe
Celltrion (068270.KS) has filed a global Phase 3 clinical trial plan for its subcutaneous infliximab formulation "CT-P1…
不做 Celltrion（068270.KS）
不做：当前仅为EMA III期临床计划提交，RA扩适应症方向已有旧闻，距离临床读出和获批商业化太远，未披露可量化短期收入或利润增量。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- Celltrion此前已向FDA提交Zymfentra扩展RA适应症的III期IND，说明RA扩适应症路线不是首次出现。
- 韩联社报道CT-P13 SC 2025年全球销售8394亿韩元、同比约增40%，市场已持续跟踪该产品增长。
- SEDaily称Celltrion在24日监管披露中表示已向EMA提交RA患者CT-P13 SC全球III期临床计划。市场反应:韩国市场已收盘，068270.KS当日收175900韩元、+2.15%，该涨幅早于新闻发布时间。
关键理由
- 本次只是向EMA提交III期临床计划，距离52周治疗期完成、申报获批和商业化仍远，短线不构成可执行重定价催化。
- Zymfentra/CT-P13 SC已有IBD适应症并在2025年实现约8394亿韩元销售、2026年预计超1万亿韩元，本次RA扩适应症是已知产品生命周期延伸而非新药获批。
- 公司2025年收入4.1625万亿韩元、2026年收入目标5.3万亿韩元；RA试验尚无新增销售额，无法量化为近期收入或利润增量。
主要风险
- 若后续EMA批准试验并出现关键临床读出或正式获批，才可能形成新的商业化催化。
- Celltrion盘后不可成交，且7月24日股价已收涨2.15%，但该涨幅发生在新闻发布前的本地交易时段，不能视为本事件反应。
原文全文
展开原文 · 1,466 字
Celltrion (068270.KS) has filed a global Phase 3 clinical trial plan for its subcutaneous infliximab formulation "CT-P13 SC (Zymfentra)" in patients with rheumatoid arthritis with the European Medicines Agency (EMA), the company said in a regulatory filing on the 24th.
The trial is designed to evaluate the efficacy and safety of CT-P13 SC in patients with moderate to severe active rheumatoid arthritis.
Celltrion plans to conduct the Phase 3 trial in a randomized, placebo-controlled, double-blind, parallel-group design involving a total of 296 patients. The treatment period is 52 weeks.
The primary objective of the trial is to demonstrate that CT-P13 SC shows superior efficacy compared to placebo based on "ACR50," which represents a 50% improvement in symptoms according to American College of Rheumatology criteria, at week 12 of treatment.
CT-P13 SC was developed as a subcutaneous formulation of the infliximab biosimilar "Remsima IV." Unlike the intravenous injection method that requires a hospital visit, it can be administered subcutaneously, enhancing patient convenience in dosing.
CT-P13 SC has completed Phase 3 trials in adult patients with ulcerative colitis and Crohn's disease and has obtained marketing approval in several countries, including the United States and Europe.
Through this Phase 3 trial, Celltrion plans to expand the indications for CT-P13 SC to rheumatoid arthritis, following its existing use for inflammatory bowel disease.
The trial is designed to evaluate the efficacy and safety of CT-P13 SC in patients with moderate to severe active rheumatoid arthritis.
Celltrion plans to conduct the Phase 3 trial in a randomized, placebo-controlled, double-blind, parallel-group design involving a total of 296 patients. The treatment period is 52 weeks.
The primary objective of the trial is to demonstrate that CT-P13 SC shows superior efficacy compared to placebo based on "ACR50," which represents a 50% improvement in symptoms according to American College of Rheumatology criteria, at week 12 of treatment.
CT-P13 SC was developed as a subcutaneous formulation of the infliximab biosimilar "Remsima IV." Unlike the intravenous injection method that requires a hospital visit, it can be administered subcutaneously, enhancing patient convenience in dosing.
CT-P13 SC has completed Phase 3 trials in adult patients with ulcerative colitis and Crohn's disease and has obtained marketing approval in several countries, including the United States and Europe.
Through this Phase 3 trial, Celltrion plans to expand the indications for CT-P13 SC to rheumatoid arthritis, following its existing use for inflammatory bowel disease.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。